-5%
Tirzema is prescribed as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
- It has not been studied in patients with a history of pancreatitis.
- It is not intended for use in patients with type 1 diabetes mellitus.
Tirzema contains tirzepatide, a dual agonist that activates both GIP (Gastric Inhibitory Polypeptide) and GLP-1 (Glucagon-like Peptide-1) receptors. This 39-amino-acid modified peptide has a C20 fatty diacid moiety that allows it to bind with albumin, which helps prolong its half-life in the body.
Tirzepatide enhances insulin secretion (both first and second) and reduces glucagon levels, both in a glucose-dependent manner, meaning these effects are more pronounced when blood sugar levels are high. It plays a significant role in regulating glucose metabolism and improving glycemic control.
